182 related articles for article (PubMed ID: 25558828)
1. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.
Bhattacharjee V; Zhou Y; Yen TJ
Cell Cycle; 2014; 13(24):3839-56. PubMed ID: 25558828
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
Parsels LA; Morgan MA; Tanska DM; Parsels JD; Palmer BD; Booth RJ; Denny WA; Canman CE; Kraker AJ; Lawrence TS; Maybaum J
Mol Cancer Ther; 2009 Jan; 8(1):45-54. PubMed ID: 19139112
[TBL] [Abstract][Full Text] [Related]
3. Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer.
Rabinowicz N; Mangala LS; Brown KR; Checa-Rodriguez C; Castiel A; Moskovich O; Zarfati G; Trakhtenbrot L; Levy-Barda A; Jiang D; Rodriguez-Aguayo C; Pradeep S; van Praag Y; Lopez-Berestein G; David A; Novikov I; Huertas P; Rottapel R; Sood AK; Izraeli S
Oncotarget; 2017 Apr; 8(16):27380-27392. PubMed ID: 28423708
[TBL] [Abstract][Full Text] [Related]
4. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Liu XJ; Nowak B; Wang YQ; Plunkett W
Chin J Cancer; 2012 Aug; 31(8):373-80. PubMed ID: 22739266
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells.
Larson AC; Knoche SM; Brumfield GL; Doty KR; Gephart BD; Moore-Saufley PR; Solheim JC
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542184
[TBL] [Abstract][Full Text] [Related]
6. DNA damage enhanced by the attenuation of SLD5 delays cell cycle restoration in normal cells but not in cancer cells.
Gong ZY; Kidoya H; Mohri T; Han Y; Takakura N
PLoS One; 2014; 9(10):e110483. PubMed ID: 25334017
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p300 increases cytotoxicity of cisplatin in pancreatic cancer cells.
Bugbee T; Gathoni M; Payne C; Blubaugh M; Matlock K; Wixson T; Lu A; Stancic S; Chung PA; Palinski R; Wallace N
Gene; 2023 Dec; 888():147762. PubMed ID: 37666373
[TBL] [Abstract][Full Text] [Related]
8. Exploiting TLK1 and Cisplatin Synergy for Synthetic Lethality in Androgen-Insensitive Prostate Cancer.
Bhoir S; Ogundepo O; Yu X; Shi R; De Benedetti A
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38001987
[TBL] [Abstract][Full Text] [Related]
9. A genetic roadmap to the response to genotoxic agents in human cells.
Ciccia A; Greenberg RA; Lees-Miller SP; Nussenzweig A
Fac Rev; 2022; 11():35. PubMed ID: 36532708
[TBL] [Abstract][Full Text] [Related]
10. Expression of vitamin D receptor as a potential prognostic factor and therapeutic target in pancreatic cancer.
Wang K; Dong M; Sheng W; Liu Q; Yu D; Dong Q; Li Q; Wang J
Histopathology; 2015 Sep; 67(3):386-97. PubMed ID: 25641222
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.
Bendell J; O'Reilly EM; Middleton MR; Chau I; Hochster H; Fielding A; Burke W; Burris H
Ann Oncol; 2015 Apr; 26(4):804-811. PubMed ID: 25573533
[TBL] [Abstract][Full Text] [Related]
12. Survival analysis of 272 patients with pancreatic cancer undergoing combined treatment.
Cao N; Zhao A; Zhao G; Wang X; Han B; Lin R; Zhao Y; Yang J
Integr Cancer Ther; 2015 Mar; 14(2):133-9. PubMed ID: 25567328
[TBL] [Abstract][Full Text] [Related]
13. Drug metabolism and homologous recombination repair in radiosensitization with gemcitabine.
Im MM; Flanagan SA; Ackroyd JJ; Shewach DS
Radiat Res; 2015 Jan; 183(1):114-23. PubMed ID: 25564718
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Tabernero J; Chiorean EG; Infante JR; Hingorani SR; Ganju V; Weekes C; Scheithauer W; Ramanathan RK; Goldstein D; Penenberg DN; Romano A; Ferrara S; Von Hoff DD
Oncologist; 2015 Feb; 20(2):143-50. PubMed ID: 25582141
[TBL] [Abstract][Full Text] [Related]
15. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of thymidylate synthase by 2',2'-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine.
Honeywell RJ; Ruiz van Haperen VW; Veerman G; Smid K; Peters GJ
Int J Biochem Cell Biol; 2015 Mar; 60():73-81. PubMed ID: 25562513
[TBL] [Abstract][Full Text] [Related]
17. Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in non-small-cell lung cancer cells.
Meng X; Wang G; Guan R; Jia X; Gao W; Wu J; Yu J; Liu P; Yu Y; Sun W; Dong H; Fu S
Pharmacogenomics; 2015 Jan; 16(1):23-34. PubMed ID: 25560468
[TBL] [Abstract][Full Text] [Related]
18. Loss of autophagy causes a synthetic lethal deficiency in DNA repair.
Liu EY; Xu N; O'Prey J; Lao LY; Joshi S; Long JS; O'Prey M; Croft DR; Beaumatin F; Baudot AD; Mrschtik M; Rosenfeldt M; Zhang Y; Gillespie DA; Ryan KM
Proc Natl Acad Sci U S A; 2015 Jan; 112(3):773-8. PubMed ID: 25568088
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D metabolic pathway genes and pancreatic cancer risk.
Arem H; Yu K; Xiong X; Moy K; Freedman ND; Mayne ST; Albanes D; Arslan AA; Austin M; Bamlet WR; Beane-Freeman L; Bracci P; Canzian F; Cotterchio M; Duell EJ; Gallinger S; Giles GG; Goggins M; Goodman PJ; Hartge P; Hassan M; Helzlsouer K; Henderson B; Holly EA; Hoover R; Jacobs EJ; Kamineni A; Klein A; Klein E; Kolonel LN; Li D; Malats N; Männistö S; McCullough ML; Olson SH; Orlow I; Peters U; Petersen GM; Porta M; Severi G; Shu XO; Visvanathan K; White E; Yu H; Zeleniuch-Jacquotte A; Zheng W; Tobias GS; Maeder D; Brotzman M; Risch H; Sampson JN; Stolzenberg-Solomon RZ
PLoS One; 2015; 10(3):e0117574. PubMed ID: 25799011
[TBL] [Abstract][Full Text] [Related]
20. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
Winograd R; Byrne KT; Evans RA; Odorizzi PM; Meyer AR; Bajor DL; Clendenin C; Stanger BZ; Furth EE; Wherry EJ; Vonderheide RH
Cancer Immunol Res; 2015 Apr; 3(4):399-411. PubMed ID: 25678581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
